While patients with formerly IDH1/2 wildtype tumors WHO grade II and III are younger (45 years), those with WHO grade IV tumors tend to be older (IDH1/2 wt astrocytoma with molecular features of a WHO grade IV tumor: 58 years; IDH1/2 wt glioblastomas: 55 years) [31, 32]. This evidence concerns the gene IDH1 and glioblastoma.